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PURPOSE: Vulnerable plaques are characterized by a myxoid matrix, necrotic lipidic core, reactive oxygen species, and high
levels of microorganisms. Aerobic microbes such as Chlamydophila pneumoniae and Mycoplasma pneumoniae usually do not
survive in oxidative stress media. Archaea are anaerobic microbes with powerful anti-oxidative enzymes that allow detoxification
of free radicals whose presence might favor the survival of aerobic microorganisms. We searched for archaeal organisms in
vulnerable plaques, and possible associations with myxoid matrix, chlamydia, and mycoplasma bodies.
METHODS: Twenty-nine tissue samples from 13 coronary artherectomies from large excentric ostial or bifurcational lesions
were studied using optical and electron microscopy. Infectious agents compatible with archaea, chlamydia, and mycoplasma were
semiquantified using electron micrographs and correlated with the amounts of fibromuscular tissue, myxoid matrix, and foam
cells, as determined from semi-thin sections. Six of the cases were also submitted to polymerase chain reaction with archaeal
primers.
RESULTS: All 13 specimens showed archaeal-compatible structures and chlamydial and mycoplasmal bodies in at least 1
sample. There was a positive correlation between extent of the of myxoid matrix and archaeal bodies (r = 0.44, P = 0.02); between
archaeal and mycoplasmal bodies (r = 0.41, P = 0.03), and between chlamydial bodies and foam cells (r = 0.42; P = 0.03). The
PCR test was positive for archaeal DNA in 4 of the 6 fragments.
DISCUSSION: DNA and forms suggestive of archaea are present in vulnerable plaques and may have a fundamental role in the
proliferation of mycoplasma and chlamydia. This seems to be the first description of apparently pathogenic archaea in human
internal organ lesions.
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INTRODUCTION
Vulnerable plaques are rich in foam cells,1 necrotic li-
pid tissue, oxidized LDL (oxLDL),2 and inflammation.3,4
The presence of oxLDL has been related to the inflamma-
tion at the subendothelial space5 where microaggregated
LDL is internalized by macrophages and smooth muscle
cells forming the foam cells.6,7 Native LDL is considered
nonatherogenic, but the presence of metals and reactive
oxygen species (ROS) modifies the LDL resulting in
oxLDL, which is quickly internalized by macrophages8,9
that become chemoattractive for monocytes and T
lymphocytes, which stimulates smooth cell proliferation
and induces production of autoantibodies and immune com-
plexes that facilitate LDL internalization by macrophages.
The recruitment of inflammatory cells may result in con-
tinued oxidation of LDL and maintenance of the athero-
sclerotic lesion process.10
Infectious agents have been frequently detected in coro-
nary atheromas, mainly Chlamydophila pneumoniae (CP)11-13
with controversial interpretations;14-16 Helicobacter pylori,
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Escherichia coli, and cytomegalovirus have been occasion-
ally associated with cardiovascular events.17 Co-infections
have also been described, for example, with Mycoplasma
pneumoniae (MP) and CP, which have been detected in
coronary vulnerable plaques18,19 and in calcified foci of sten-
otic aortic valves in elderly patients.20,21 Multiple co-infec-
tions by mycoplasma, chlamydia, and viruses have been
described in patients with chronic diseases,22 and a higher
prevalence of seropositivity for MP was observed in coro-
nary artery disease of patients seropositive for CP.23 There-
fore, the question arises as to whether infectious agents
might be related to the development of ROS and oxLDL.
Chlamydophila pneumoniae has already been related to the
LDL oxidation process.24 Although CP and MP have been
found in large amounts in vulnerable atherosclerotic
plaques, they have also been detected in lower quantities
in nonatherosclerotic vessels, suggesting that a co-factor
could be determining their proliferation.25
It is intriguing to ponder that since vulnerable plaque
is a rich ROS media, how is it that chlamydia, mycoplasma,
and other microorganisms may exhibit greater proliferation
at those sites? Relatively low steady-state levels of intrac-
ellular superoxide or H2O2 causes oxidative stress—defined
as an imbalance between oxidants and antioxidants in favor
of the oxidants, potentially leading to damage26 with reduc-
tion in the growth of aerobic or anaerobic bacteria.27
Superoxide dismutases (SOD) play an essential role in
the defense against oxygen toxicity and have been found
in the cytosol of anaerobic microorganisms, including
archaeal representatives.28 Archaea occupy the deepest and
shortest branches of the universal phylogenetic tree.29 One
of their most particular characteristics is the ability to oxi-
dize hydrogen and reduce metals such as Fe and Mn.30,31
The presence of SOD in archaea is a significant finding,
as they exhibit unique properties of stability to extreme con-
ditions.
In the present work, we explored whether archaeal or-
ganisms may be participating in the pathogenesis of athero-
sclerotic plaque vulnerability and proliferation of other in-
fectious agents such as mycoplasma and chlamydia.
METHODS
This work was performed in patients , most of them
with symptoms of unstable angina, undergoing interven-
tional pre-stenting directional coronary atherectomy in os-
tial or bifurcational excentric atherosclerotic plaques at the
Heart Institute (InCor), Hospital das Clínicas, São Paulo,
University Medical School, after approval by the Ethical
and Scientific Committee. Two or 3 fragments were ob-
tained from each of 13 patients (10 men and 3 women,
mean age, 64 +/- 12 years and 69 +/- 12 years, respectively,
with a total of 29 fragments being studied. The specimens
were fixed in 2% glutaraldehyde, processed to be embed-
ded in araldite, and submitted to semi-thin and thin sec-
tioning, which were analyzed by optical and transmission
electron microscopy, respectively. In 6 of the 13 cases, sam-
ples were frozen in –70o C liquid nitrogen for polymerase
chain reaction (PCR) studies.
Semi-thin sections were analyzed by optical
microscopy. The variables, fibromuscular tissue, lipidic
core, myxoid matrix (MM), and foam cells, were
semiquantified as follows: absent (0), less than 5% (1+),
less than 25% (2+), or more than 25% (3+) of the sample.
Infectious agents bodies compatible with archaea,
chlamydia, and mycoplasma were semiquantified from 5
representative electron micrographs, magnified 15,000
times, as absent (0), scarce (1+), moderate (2+), or severe
(3+). Detailed aspects of the microorganisms were observed
at 90,000 times magnification. The fragments were subdi-
vided into 2 groups, without or with some area of myxoid
matrix, which is indicative of plaque instability. These
groups were compared regarding the frequency of archaeal
elements.
Tissue preparation for optical and transmission
electron microscopy
Tissue fragments less than 0.1 cm thickness were fixed
in 2% glutaraldehyde for 2 hours, postfixed in 1% osmium
tetroxide, dehydrated, and embedded in araldite resin.
Semi-thin sections (0.5 um. thickness) were stained with
toluidine blue, and ultrathin sections (70 nm thickness)
were stained with uranyl acetate and lead citrate.
Polymerase chain reaction (PCR) technique
DNA from the frozen tissues was obtained using the
Dneasy Tissue kit (QIAGEN) following manufactor instruc-
tions. PCR was performed using 20 mM Tris-HCl (pH 8.4),
50 mM KCl, 2.0 mM MgCl, 200 mM of each dNTP, 1.0
pmol of each primer (1100F: 5’-
AGTCAGGTAACGAGCGAG- 3’; 1400R: 5’-
GTGCAAGGAGCAGGGAC-3’), 2.5 U of Platinum Taq
DNA Polymerase (Invitrogen), and 5mL of DNA, in a fi-
nal volume final of 25ml. The amplification was carried
out with a PTC - 100 (MJResearch, Inc) thermocycler, us-
ing the following program: 95°C for 10 minutes, followed
by 40 cycles at 95°C for 60 s, 55°C for 1 minute and 30 s,
72°C for 60 s, and 72°C for 10 minutes. The reaction was
analyzed on 2% agarose stained with ethidium bromide,
with ultraviolet (UV) transillumination. As a positive con-
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trol, we used a culture of Halobacterium salinarum (posi-
tive reaction at 300 pb), kindly provided by Prof. Maysa
Beatriz Mandetta Clementino, from the Bacteria and
Archaea Reference Section of Microbiology Department,
National Institute of Quality Control in Health, Oswaldo
Cruz Foundation – FIOCRUZ, Rio de Janeiro.
Statistical analysis
The Spearman correlation test was used to test the
number of infectious agent bodies from electron
microscopy versus the histological aspects of plaque vul-
nerability. The Student t test was used to identify a possi-
ble association between archaeal elements and myxoid
matrix and other infectious agents, ie, mycoplasmal and
chlamydial bodies.
RESULTS
Electron microscopy revealed numerous elements com-
patible with archaea, i.e., rounded elements showing dimen-
sional variation, surrounded by an irregular folded
monolipid membrane, which frequently presented
invaginations forming large rounded and flattened vesicles
into a homogeneous clear cytoplasmic material. The mor-
phology of these elements varied according to the section
axis. (Figure 1).
The archaeal elements were frequently seen in close
contact with chlamydial elementary bodies, which have a
typical form, i.e., round dark structures enclosed by a dou-
ble membrane with an small expansion that gives the char-
acteristic pear shape to C. pneumoniae; alternatively, they
were frequently seen with mycoplasmal forms character-
ized by rounded elements with granulous cytoplasmic ma-
terial enclosed by a unique membrane (Figure 2A).
The PCR test for archaeal DNA was positive in 4 of
the 6 cases. Figure 2B shows the PCR results, the first sam-
ple being the positive control. Our samples showed a con-
stant positive reaction at 400 pb, using the same 1.110F
and 1.400R generic archaeal primers that show positivity
in the control at 300 pb. We divided the analyzed fragments
into 2 groups, MM-negative samples and MM-positive sam-
ples. The semiquantitative analysis showed a significantly
higher amount of archaeal-suggestive bodies and lipidic
necrotic core in the MM-positive group than in the MM-
negative group, with no difference regarding mycoplasmal
and chlamydial bodies (Table 1). Considering all fragments,
positive correlations were observed between extent of MM
regions and the amount of archaeal-suggestive bodies (r =
0.44, P = 0.02); archaeal and mycoplasmal bodies (r = 0.41,
P = 0.03), and chlamydial bodies and foam cells (r = 0.42;
P = 0.03).
DISCUSSION
Atherosclerosis has different characteristics among in-
dividuals and among areas in a same individual and is re-
lated to oxidative LDL.32 How infectious agents may par-
ticipate in the pathogenesis of different atherosclerotic vul-
nerability is our focus in this work. Chlamydophila
pneumoniae has been related to the LDL oxidation proc-
ess,23 and previously we have identified LDL particles in
Figure 1 - Electron micrograph exhibiting rounded and flattened bodies
suggestive of archaeal origin sectioned in different positions: 1A) 2 elements
transversally sectioned enveloped by a monolayer lipid membrane that
invaginates (arrows) forming large, clear intracytoplasmic vacuoles (empty
arrows). 1B) Close view of an archaeal-suggestive element sectioned at the
level of folded external membrane entrances (arrows) 1C) Close view of an
archaeal-suggestive element sectioned on the sagittal axis, revealing a
flattened and folded aspect (arrow). 10000x original magnification
Figure 2 - A) Electron micrograph of a vulnerable plaque exhibiting a
Chlamydophila pneumoniae elementary body in close contact with an
archaeal-suggestive element, which contains intracytoplasmic vacuoles. A
mycoplasmal element is also present. 2B) PCR test for archaeal DNA was
positive in 4 of the 6 cases (arrow points to the 400 bp product; left channel
is the positive control).
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the serum of atherosclerotic elderly patients with antigens
of MP in association with C-reactive protein.33 Archaea is
a highly diverse and abundant group of prokaryotes, includ-
ing a number of extremophiles that thrive in hostile envi-
ronments such as hot springs, salt lakes, submarine volcanic
habitats, in addition to more physiological sites.34 Despite
being one of the most numerous and ubiquitous life forms
on earth, the domain Archaea is generally assumed not to
cause human disease.35-37 They have been described in lu-
minal intestinal microbial ecosystems producing methane,
having CO2 as the main carbon substrate.38 Genomes of
archaea have been described in persistent pathogens and it
is suggested that they may confer metabolic capabilities as
adaptational strategies for survival even in hostile host
niches by breaching host barriers that exclude other organ-
isms. 39 Recently, genetic sequences of members of domain
archaea were found in necrotic material from apical peri-
odontitis, suggesting that archaea may play a role as a hu-
man pathogen.40 In the present study we detected archaea
sugestive microorganisms in human atherosclerotic lesions.
We analyzed atheroma-vulnerable tissues obtained from
interventional atherotomy procedures and identified 16S
rRNA archaeal genomic sequences by PCR assay in 4 of
the 6 cases analyzed. Usually, archaeal sequences exhibit
300 pb in PCR technique, as indicated by our positive con-
trol of a cultive from H. sulpholobus. However, our cases
showed a constant positivity at 400 pb, with the same se-
quences of archaeal primers, suggesting a different size of
archaeal DNA.
Archaeal morphology has not been very well described,
and the rare ultrastructural descriptions were of archaea
from artificial cultures.41 In our cases, transmission elec-
tron microscopy exhibited numerous structures compatible
with archaea in 100% of the cases. Archaea have a unique
phospholipid membrane that can be structurally modified,
allowing adaptation to high temperatures and high salin-
ity; it is quite differently composed compared to a bacte-
rial membrane.42 So it is reasonable to suppose that changes
in the morphology, lipid composition, and fluidity of
archaeal membranes occur according to the environmen-
tal needs.43 The archaeal-compatible bodies present at the
vulnerable plaques were characterized by roundness and
contained large clear intracytoplasmic vacuoles that might
have contained gases. Although the membrane-related proc-
esses in archaea are poorly understood, inverted vesicle
membranes have been described.44 This is in agreement
with our observations, since the intracytoplasmic vacuoles
seemed to be derived from invagination of the external en-
veloping membrane. Close associations between archaea
and chlamydial or mycoplasmal bodies were frequently
found. Myxoid matrix (MM) is a collagen alteration usu-
ally present in vulnerable plaques and a fundamental le-
sion of many other diseases with still unknown etiologies,
such as prolapse valvar, aortic dissection, and arterial an-
eurysms. A significant association of archaeal-like elements
containing large clear intracytoplasmic vacuoles with MM
regions suggests a cause-effect relationship. We speculate
that archaea may favor the survival and proliferation of
chlamydia and mycoplasma at the vulnerable atheroscle-
rotic plaques since archaea possess superoxide dismutases
that would protect them from intra- and extracellular
oxidative stress.28 In addition to the significant correlation
between archaeal organisms and quantity of MM regions in
the plaque, archaea correlated with the number of mycoplas-
mal bodies. Metalloproteinases have been found in associa-
tion with mycoplasmal infection,45 are present in archaea 46
and they are increased in valvar and aortic MM lesions.47
Foam cells, another characteristic of vulnerable plaque, cor-
related with numbers of chlamydial bodies. These findings
favor our hypothesis that archaea may be an important co-
factor for the pathogenesis of plaque vulnerability, induc-
ing proliferation of other microorganisms, which may favor
the development of myxoid matrix lesions.
CONCLUSION
This pioneering description of archaeal elements in
atherosclerotic lesions indicates that archaea may be a
pathogenic organism involved in the pathogenesis of plaque
vulnerability by favoring development of ROS and survival
of aerobic microorganisms such as mycoplasma and
chlamydia. This finding opens new directions for the com-
prehension of infection in the pathogenesis of atheroscle-
rosis and myxoid matrix degeneration.
Table 1 - Mean and standard deviation of semiquantitative results
Group Lipid core FM MM Foam cell archaea CP Mycoplasma
MM neg (n = 14) 0.57 + 0.76 2.5 + 1.09 0 + 0 0.86 + 1.10 0.5 + 0.76 1.85 + 0.99 1.23 + 0.93
MM pos (n = 15) 2.2 + 0.77 1.4 + 1.35 2.13 + 0.83 0.93 + 1.16 1.29 + 0.82 1.5 + 1.02 1.33 + 0.76
t test (P) < 0.001 0.012 < 0.001 0.43 0.007 0.19 0.21
MM neg – group of blocks negative for myxoid matrix, evaluated in semi-thin sections.
MM pos – group of blocks positive for myxoid matrix. FM – fibromuscular tissue
CP – Chlamydophila pneumoniae
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RESUMO
Higuchi ML, Santos MH, Roggério A, Kawakami JT, Be-
zerra HG, Canzian M. Um papel para organismos de ar-
queia no desenvolvimento de placas ateroscleróticas vulne-
ráveis e matriz mixomatosa. CLINICS. 2006;61(5):473-8.
PROPOSTA: Placas vulneráveis são caracterizadas por ma-
triz mixomatosa, centro lipídico necrótico, espécies reativas
de oxigênio e alto níveis de microorganismos. Micróbios
aeróbicos como Chlamydophila pneumoniae e Mycoplasma
pneumoniae usualmente não sobrevivem em meio de estresse
oxidativo. Arquéias são microorganismos anaeróbicos com
poderosas enzimas anti-oxidantes que permitem detoxi-
ficação de radicais livres e a presença delas poderia favore-
cer a sobrevivência de micróbios aeróbicos. Pesquisamos por
elementos de arquéia em placas vulneráveis e sua possível
associação com degeneração mixomatosa da matriz e aumen-
to do número de clamídias e micoplasmas.
MÉTODOS: Vinte e nove amostras de 13 produtos de
aterotomia de lesões grandes e excêntricas de óstio ou bi-
furcação de coronárias foram estudadas pela microscopia
óptica e eletrônica. Agentes compatíveis com arquéia,
clamídia e micoplasma foram semiquantificados pela
microscopia eletrônica e correlacionados com quantidade
de tecido fibromuscular, matriz mixomatosa e células
xantomatosas. Seis casos foram também submetidos à re-
ação em cadeia da polimerase com oligonucleotídeos de
arquéia.
RESULTADOS: Os 13 casos foram positivos para estru-
turas sugestivas de arquéia, micoplasma ou clamídia, em
pelo menos uma amostra. Houve correlação positiva entre
intensidade de matriz mixomatosa versus arquéia (r=0.44,
p=0.02); arquéia versus micoplasma (r=0.41, p=0.03) e
clamídia versus células xantomatosas r=0,42; 0.03). PCR
foi positiva para DNA de arqueia em 4 dos 6 fragmentos.
DISCUSSÃO: DNA e formas compatíveis com arquéia es-
tão presentes em placas vulneráveis e podem ter papel fun-
damental na proliferação de micoplasma e clamídia. Este
parece ser o primeiro relato de arquéia aparentemente
patogênica em lesões de órgãos internos humanos.
UNITERMOS: Arquéia. Aterosclerose. Matriz mixo-
matosa. Clamídia. Micoplasma.
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